Navigation Links
WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
Date:10/28/2008

BRADENTON, Fla., Oct. 28 /PRNewswire/ -- WellSpring Pharmaceutical Corporation, a growing North American-based pharmaceutical manufacturer, today announced that Wendy Shusko has been named Chief Operating Officer. Formerly, Ms. Shusko held the position of Chief Financial Officer, having joined the company in early 2000. In her new role as COO, Ms. Shusko will maintain financial responsibilities while broadening her areas of oversight to operations with an initial focus on the newly acquired consumer brands product line.

"WellSpring has been successful in the relaunch of older niche prescription products. We now have the opportunity to show equal success with our new niche consumer products portfolio," said Ms. Shusko. "I am looking forward to the challenge and am pleased to be able to take part in WellSpring's continued growth."

Ms. Shusko has over twenty years' experience of combined financial and operational experience with sixteen of those years in the pharmaceutical industry. From 1992 until joining the WellSpring team, Ms. Shusko worked in various management and financial capacities for Roberts Pharmaceutical Corporation, an international, multi-faceted pharmaceutical company, including Director of Finance and Financial Operations.

"WellSpring's success thus far can be attributed to driven efforts toward a common vision. I am now asking Ms. Shusko to apply her experience and skills to operations with the anticipation that we will continue that trend in the years to come," said Dr. Robert A. Vukovich, WellSpring's CEO and Chairman.

About the Company

WellSpring Pharmaceutical Corp has made the development, marketing and sales of new and novel prescription and OTC drug products its strategic focus. WellSpring's prescription drug products include Dyrenium (R) (diuretic) and Dibenzyline (R) (anti-hypertension) which are marketed in the US. The firm is an active acquirer of pharmaceutical brands and enhances their value through the development of product improvements and line extensions.

WellSpring is a privately held pharmaceutical company founded in 1999 by Dr. Robert A. Vukovich, the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. WellSpring owns and operates an FDA approved manufacturing plant in Oakville, Ontario, Canada. Its administrative headquarters are located in Bradenton, Florida. The firm provides contract manufacturing services to the pharmaceutical industry and manufactures prescription and OTC drug products for both the US and Canada.

Contact: Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or Wendy Shusko, +1-941-552-7881.

WellSpring Websites: http://www.wellspringpharm.com, http://www.wpcoutsourcing.com, http://www.wellskin.ca.


'/>"/>
SOURCE WellSpring Pharmaceutical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
7. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Hackensack, N.J. (PRWEB) , ... April 26, 2017 ... ... fluency, Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine ... program that recognizes the world’s top women business owners. Winners have demonstrated that ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
(Date:4/25/2017)... ... 2017 , ... The doctors at Wall Centre Dental are now expanding their ... require sedation to receive dental care. The doctors offer three treatment options to put ... to oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: